Public Release: 

Insilico Medicine to launch R&D center and announce new research results in Taiwan ROC

InSilico Medicine, Inc.

IMAGE

IMAGE: Insilico Taiwan is an Insilico Medicine subsidiary focusing on the development and validation of generative adversarial networks(GANs) and reinforcement learning for medicinal chemistry applications. view more 

Credit: Insilico Medicine

Tuesday, March 20th, 2018, Insilico Medicine, a Baltimore-based artificial intelligence company specializing in drug discovery, biomarker development and aging research will announce the launch of Insilico Taiwan, a subsidiary focusing on the development and validation of generative adversarial networks(GANs) and reinforcement learning for medicinal chemistry applications.

The opening ceremony will coincide with the presentation of new research results about GAN architectures specifically designed for the generation of novel molecules with the desired set of molecular properties.

The ceremony will transpire on Wednesday, March 21st between 1:30PM and 4PM local time in the ballroom of the Regent Hotel, Taipei. The journalists and pharmaceutical companies are invited to attend the ceremony and meet the team of Insilico Taiwan.

"We are very happy to launch our R&D center in Taipei, where there is abundant talent in medicinal chemistry and biology and the working vertically-integrated drug discovery infrastructure. The recent advances of artificial intelligence will help to turn this infrastructure into the global pharmaceutical powerhouse. We would like to thank the Department of Commercialization of Biotechnology (DCB) for their support and effective collaboration in the application of AI to drug discovery", said Alex Zhavoronkov, PhD, founder and CEO of Insilico Medicine and adjunct professor of the Buck Institute for Research on Aging.

Insilico Medicine is one of the first AI companies to combine the expertise in artificial intelligence applied to the cutting-edge medicinal chemistry and disease signature development and target identification with deep domain knowledge in and focus on aging and age-related diseases.

"I am happy to take the role of head of Insilico Taiwan and establish the local deep learning team. It will be integrated into the local drug discovery ecosystem and will help building the pharmaceutical industry of the future. Taiwan consistently demonstrated its leadership in technology with the examples in electronics industry and I am very happy to contribute to the effort to repeat these miracles in the pharmaceutical space", said Artur Kadurin, the head of Insilico Taiwan.

Very recently Insilico Medicine published series of research papers describing novel approaches in aging biomarker development using deep neural networks and got several new papers accepted in major scientific journals. Some of these results will be presented at the opening ceremony.

###

About Insilico Medicine

Insilico Medicine, Inc. is an artificial intelligence company headquartered at the Emerging Technology Centers at JHU in Baltimore, with R&D and management resources in Belgium, Russia, UK, Taiwan and Korea sourced through hackathons and competitions. The company utilizes advances in genomics, big data analysis, and deep learning for in silico drug discovery and drug repurposing for aging and age-related diseases. Insilico pioneered the applications of the generative adversarial networks (GANs) and reinforcement learning for generation of novel molecular structures for the diseases with a known target and with no known targets. In addition to working collaborations with the large pharmaceutical companies, the company is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with LifeExtension.com the company launched a range of nutraceutical products. It also provides a range of consumer-facing applications including Young.AI and Aging.AI.

The company raised venture capital and partnered with Juvenescence Limited, a holding company focused on longevity biotechnology. The company aspires to become the "Bell Labs" for artificial intelligence and associated technologies for healthcare and longevity biotechnology and commercialize its research by forming subsidiaries around the specific technologies and licensing the intellectual property, molecules and data to the biotechnology and pharmaceutical companies. In 2018, the company was named the one of the global top 100 AI companies by CB Insights. Website: http://www.Insilico.com

For further information, images or interviews, please contact: Please contact: Qingsong Zhu, PhD zhu@pharma.ai

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.